p53 is an indicator of tumor progression in early but not advanced gastric carcinomas

Hepato-Gastroenterology

Volumn 54, Issue 79, 2007, Pages 2159-2163

  Ishii, Hideaki H ^a   Gobe, Glenda C ^b   Ebihara, Yoshiro ^c  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Gastric adenocarcinoma; Gastric cancer; Immunohistochemistry; p53; Proliferation

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUCOSA; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR GROWTH;

ADENOCARCINOMA; APOPTOSIS; CELL PROLIFERATION; DISEASE PROGRESSION; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37749031279     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lane DP: p53 and human cancers. Br Med Bull 1994; 50:582-599.
2. Liu MC, Gelmann EP: p53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002; 29:246-257.
3. Vermeulen K, Berneman ZN, Van Bockstaele DR: Cell cycle and apoptosis. Cell Prolif 2003; 36:65-175.
4. Bernardini S, Adessi G-L, Billerey C, Chezy E, Carbillet J-P, Bittard H: Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 1999; 162:1496-1501.
5. Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S: p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 1995; 8:170-176.
6. Vet JAM, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FMJ, Schalken JA: Comparison of p53 protein overexpression with p53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 1995; 73:837-843.
7. Abdel-Fattah R, Challen C, Griffiths TRL, Robinson MC, Neal DE, Lunec J: Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in absence of detected mutations is associated with poor prognosis. Br J Cancer 1998; 77:2230-2238.
8. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-967.
9. Tamura G: Alterations in tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12:192-198.
10. International Union Against Cancer. In: Sobin LH, Wittekind CH (Eds.). TNM classification of malignant tumors. 5th Edition. New York: John Wiley & Sons, Inc., 1997.
11. Ishii HH, Gobe GC, Yoneyama Y, Mukaide M, Ebihara Y: Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas. J Clin Pathol 2005; 57:1306-1311.
12. Kerr J, Gobe GC, Winterford CM, Harmon BV: Anatomical methods in cell death. Methods Cell Biol 1995; 46:1-27.
13. Gobe G, Zhang X-J, Willgoss DA, Schoch E, Hogg NA, Endre ZH: Relationship between expression of bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol 2000; 11:454-467.
14. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R: In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995; 21:1465-1468.
15. Landberg G, Roos G: Proliferating cell nuclear antigen and Ki-67 antigen expression in human haematopoietic cells during growth stimulation and differentiation. Cell Prolif 1993; 26:427-437.
16. Hiroshima K, Iyoda A, Toyozaki T, Supriatna Y, Shibuya K, Shimamura F, Haga Y, Yoshida S, Fujisawa T, Ohwada H: Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol 2002; 15:1326-1332.
17. Aizawa K, Ueki K, Suzuki S, Yabusaki H, Kanda T, Nishimaki T, Suzuki T, Hatakeyama K: Apoptosis and bcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 1999; 14:85-91.
18. Iamaroon A, Pongsiriwet S, Mahanupab P, Kitikamthon R, Pintong J: Oral non-Hodgkin lymphomas: studies of EBV and p53 expression. Oral Dis 2003; 9:14-18
19. Sugai T, Habano W, Jiao YF, Suzuki M, Takagane A, Nakamura S: Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers. Oncology 2005; 68:548-557.
20. Gao JP, Uchida T, Wang C, Jiang SX, Matsumoto K, Satoh T, Minei S, Soh S, Kameya T, Baba S: Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 2000; 16:469-475.
21. Babjuk M, Soukup V, Mares J, Duskova J, Sedlacek Z, Trkova M, Pecen L, Dvoracek J, Hanus T, Kocvara R, Novak J, Povysil C: The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 2002; 34:495-501.
22. Doak SH, Jenkins GJ, Parry EM, Griffiths AP, Shah V, Baxter JN, Parry JM: Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer 2003; 89:1729-1735.
23. Soong R, Bobbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ: Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Human Pathol 1996; 27:1050-1055.
24. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993; 53:2614-2617.
25. Kelsey KT, Park S, Nelson HH, Karagas MR: A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 2004; 90:1572-1576.